PRSS1 and neoplasm: Tumors treated with tumor-specific IgE-sensitized MCs compared to controls also had several downregulated signaling intermediates including those shown to promote tumor growth and progression in tumor microenvironments [PRSS2 (41), PRSS1 (42), REG4 (43), PRKAR2B (44), NDUFA4L2 (45), LRFN5 (46), and ANGPTL4 (47)].